Alnylam Pharmaceuticals, Inc. stock price

Alnylam Pharmaceuticals, Inc. latest news:


  • 09/20/2017 11:30:45

    Why Alnylam Pharmaceuticals Is Wednesday’s Top Stock


  • 09/20/2017 05:39:06

    UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment

    Sanofi and Alnylam Pharmaceuticals Inc. on Wednesday reported positive results in a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy. Alnylam shares jumped 24% after resuming trading following a halt. In a joint statement, the companies said an investigational RNAi therapeutic met its primary and secondary endpoints. The disease is an inherited one that is progressively debilitating and often fatal and is caused by mutations in the TTR gene. TTR protein is produced in the liver and usually acts as a carrier for vitamin A. Mutations can cause proteins to accumulate and damage organs and tissue, including the heart. About 50,000 people worldwide suffer from the disease, which currently has no approved treatment apart from liver transplant. Patients typically have a life expectancy of 2.5 to 15 years after the first symptoms appear. "This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases," said Elias Zerhouni, M.D., president, global R&D at Sanofi in a statement. Alnylam shares had gained 100.4% in 2017 through Tuesday, while the S&P 500 has gained 12%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/07/2017 15:08:00

    What Happened in the Stock Market Today

    On a mixed day for the market, RH soared thanks to a surprisingly good quarter, while Alnylam Pharmaceuticals fell after it halted trials of a new drug.

  • 09/07/2017 05:33:09

    Alnylam Pharmaceuticals' stock plunges after 'fatal' event in hemophilia drug program

    Shares of Alnylam Pharmaceuticals Inc. plunged 13% in premarket trade Thursday, after the RNAi therapeutics company said it has suspended fitusiran dosing after a "fatal thrombotic event." The patient had hemophilia A without inhibitors in a phase 2 open-label extension study of fitusiran. The company said considering fitusiran's "benefit-risk" profile, it aims to resume dosing as soon as possible after consulting with regulatory authorities. Regarding givosiran for the treatment of acute hepatic porphyrias, Alnylam said it has reached alignment with the Food and Drug Administration on a phase 3 study design. Alnylam's stock had more than doubled year to date through Wednesday, while the S&P 500 had gained 10%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Alpha and Omega Semiconductor LimitedAOSL | AlphaMark Actively Managed Small Cap ETFSMCP | Alphatec Holdings, Inc.ATEC | Altera CorporationALTR | Altisource Portfolio Solutions S.A.ASPS | Altra Industrial Motion Corp.AIMC | AMAG Pharmaceuticals, Inc.AMAG | Amarin Corporation PLCAMRN | A-Mark Precious Metals, Inc.AMRK | Amaya Inc.AYA |